Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ganovo Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program

Ascletis Pharma
Posted on: 27 Sep 18

HANGZHOU and SHAOXING, China, Sept. 25, 2018 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) announced today that Ganovo® (Danoprevir) has been enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program ("Pilot Program") for outpatients with hepatitis C. The Pilot Program supports hepatitis C patients get timely access to most innovative treatments and aims to eliminate hepatitis C in China by 2030. It also creates a new chapter for Ganovo® to begin its reimbursement access to the provincial medical reimbursement system. It is anticipated more provinces in China will replicate the Tianjin initiative.

Ganovo® is the first DAA developed and commercialized by a domestic company in China. Ganovo® inhibits the hepatitis C virus (HCV) NS3/4A protease that is critical to HCV replication. In the phase III clinical trial conducted in Mainland China, Ganovo regimen (Ganovo® in combination with PEGylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in genotype 1 non-cirrhotic patients, with a 12-week treatment duration.

"Thanks to the Tianjin Medical Insurance Authority and clinical community for their support to domestically developed innovative drugs. The reimbursement reflects the clinical experts' endorsement of Ganovo's efficacy and safety, as well as the government's support for innovative drugs and care for patients," said Jinzi J. Wu, Ph.D., Ascletis' founder, Chairman and CEO. "The Pilot Program fulfilled the concept of value-based payment. Starting from Tianjin, we anticipate Ganovo® will gain reimbursement access in more provinces and benefit more hepatitis C patients in China."

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 27/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.